Skip to main content


Question for Department of Health and Social Care

UIN 178754, tabled on 12 April 2021

To ask the Secretary of State for Health and Social Care, what assessment has been made of the potential merits of making mercaptamine hydrochloride eye drops available through the NHS.

This answer is the replacement for a previous holding answer.

Answered on

22 April 2021

Current clinical commissioning policy is that mercaptamine hydrochloride eye drops are not recommended to be available as a treatment option through routine commissioning for corneal cystine deposits, following the prioritisation process undertaken by NHS England and NHS Improvement in July 2020. However, NHS England and NHS Improvement have determined that there is sufficient clinical evidence to consider commissioning mercaptamine hydrochloride eye drops. This treatment will therefore be considered at the Clinical Priorities Advisory Group prioritisation meeting in May 2021, along with a number of other treatments being considered for funding.

Answered by

Department of Health and Social Care
Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.